Home Archives – Page 2 of 3 – Treatment Action Group

cover of: Test and Treat Mild or Moderate COVID-19: Paxlovid (nirmatrelvir/ritonavir)

Test and Treat COVID-19: Community Guide to Paxlovid

April 11, 2022
Dorrit Walsh

Paxlovid can reduce the risk of hospitalization or death by 89% when taken shortly after testing positive for COVID-19. This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about Paxlovid: what it is,…

Talk About It with TAG: The Impact of Long COVID on People Living With HIV

March 3, 2022
Dorrit Walsh

On March 3, 2022, we presented the first "Talk About It with TAG" webinar. This series addresses the needs of community members by having open discussions with researchers and community experts on issues related to COVID-19 and HIV biomedical research.

Mourning Paul Farmer, Honoring His Legacy

February 23, 2022
Dorrit Walsh

TAG’s staff and board of directors are filled with grief at the premature death of Dr. Paul Farmer, who illuminated and changed our world with his combination of passion, intelligence, solidarity with the poor, and determined will for social justice.

Does Delta Mean Change? Community Update on the Delta Variant

August 31, 2021
Dorrit Walsh

On August 31, 2021, Treatment Action Group (TAG) and Black AIDS Institute (BAI) held a community discussion to get the latest updates on the impact of the Delta variant.

TAG Celebrates TB Advocacy Award for Senior Policy Officer Elizabeth Lovinger

June 25, 2021
Dorrit Walsh

TAG joins the U.S. National TB Controllers Association (NTCA) in celebrating our dedicated and brilliant Senior Government Relations and Policy Officer, Elizabeth (Lizzy) Lovinger, who today received the 2021 Charles DeGraw TB Advocacy Award.

Breaking Barriers: Surveying Community Perspectives of COVID-19 Vaccine Research

May 19, 2021
Dorrit Walsh

This report aims to raise the profile of discussions that have been taking place regarding community understanding and involvement in COVID-19 vaccine research. It presents the results of an online survey developed by TAG, along with the Black AIDS Institute and the COVID-19 Prevention Trials Network in the fall of 2020 seeking community perspectives on COVID-19 vaccine development.

Unique Barriers to COVID-19 Vaccine Access for Black Communities

May 11, 2021
Dorrit Walsh

On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.

Addressing Barriers to Engagement with Faith Communities and COVID-19 Research and Vaccine Uptake

April 29, 2021
Dorrit Walsh

On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative.

US FDA COVID Vaccine Authorization Important Step Toward Ending the COVID-19 Pandemic

December 11, 2020
Dorrit Walsh

Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.

Efficacy News from Second COVID-19 Vaccine Trial Underscores Need for Transparency and Cooperation Between Outgoing and Incoming US Administrations

November 16, 2020
Dorrit Walsh

AVAC and Treatment Action Group (TAG) welcome today’s announcement that preliminary data from the efficacy trial of Moderna’s mRNA COVID-19 vaccine indicate high-level of protection against COVID-19.